The 5 Most Common Reasons Phase 1 Candidates Fail

In the fiercely competitive landscape of drug development, navigating the journey from the laboratory bench to the pharmacy shelf is a formidable challenge.

While the odds of success improve in later phases, Phase 1 trials present a critical juncture where numerous drug candidates falter.

Here, we outline the five most common reasons behind Phase 1 drug candidate failures.

The average cost of a Phase 1 Trial is

4 Million Dollars





40%

of trials fail in Phase 1



Our clinical team has over 

120

years of combined experience

Download Our Paper

Fill out this form to download our white paper on the reasons that Phase I trials fail.

5 Most Common Reasons Phase 1 Clinical Trials Fail

An Enormous
Challenge

In the highly competitive world of drug development, the journey from the laboratory bench to the pharmacy shelf is fraught with challenges.

The high failure rate of drugs in Phase 1 trials, with approximately 30% not progressing beyond this initial stage, underscores the rigorous nature of these early clinical evaluations.